X-tosis

What X-tosis does

X-tosis, Inc. is a privately held, pre-clinical precision-medicine biotechnology company founded in 2024 and headquartered in Gainesville, Florida. The company is developing first-in-class small-molecule therapeutics designed to restore mitochondrial function and prevent neuronal death in patients with neurodegenerative diseases, beginning with Parkinson's disease (via lead candidate XTS001) and extending to Alzheimer's disease, ALS, and related conditions characterized by mitochondrial dysfunction.

The company's core technology is the patented MitoXTS platform, a family of small-molecule inhibitors of VDAC1 (voltage-dependent anion channel 1) oligomerization. By stabilizing VDAC1 on the outer mitochondrial membrane, XTS compounds aim to preserve mitochondrial membrane potential, reduce reactive oxygen species, limit release of apoptotic factors, and interrupt inflammatory cascades, constituting an upstream, disease-modifying approach as opposed to symptomatic management. The platform is grounded in more than five decades of research led by Professor Varda Shoshan-Barmatz (225+ publications, 14,000+ citations) and is supported by precision biomarkers intended to guide patient selection, treatment, and monitoring. Patent protection extends through at least 2036.

X-tosis operates a partnership-driven business model: the company pursues out-licensing and pharmaceutical partnerships for development and commercialization of XTS compounds across multiple indications rather than building its own commercial infrastructure. Non-dilutive grant funding is a primary capital source, including a $2.74 million award from The Michael J. Fox Foundation for Parkinson's Research (June 2026) earmarked for advancing XTS001 through IND-enabling studies. The company supplements pipeline development with active conference presence (Biotech Showcase Seed Showcase 2025 and the J.P. Morgan Annual Healthcare Conference) to attract pharma partners and investors. The company has no product revenue and is pre-commercial, with pricing structure to be determined upon FDA approval.

Name

X-tosis

Legal name

X-tosis, Inc.

Website

https://x-tosis.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

X-tosis is a pre-clinical precision-medicine biotechnology company developing first-in-class small-molecule mitochondrial therapeutics that inhibit VDAC1 oligomerization to treat neurodegenerative diseases including Parkinson's and Alzheimer's, advancing assets via licensing and pharmaceutical partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

Gainesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Licensing and Partnership Revenue: X-tosis is a pre-clinical biotech pursuing licensing opportunities for multiple indications. The company plans to partner with pharmaceutical companies for development and commercialization of XTS compounds. Licensing opportunities are available for multiple indications.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

X-tosis develops first-in-class small-molecule therapeutics that selectively inhibit VDAC1 (voltage-dependent anion channel 1) oligomerization through its patented MitoXTS™ platform to restore mitochondrial function, reduce inflammation, and prevent neuronal death. The company is advancing its lead candidate XTS001, a brain-penetrant oral small molecule, through preclinical and IND-enabling studies targeting Parkinson's disease, Alzheimer's disease, ALS, and related neurodegenerative conditions, complemented by precision biomarkers for patient selection and treatment monitoring.

Product overview

X-tosis is a precision-medicine biotechnology company developing first-in-class mitochondrial therapeutics through its patented MitoXTS™ platform. The platform centers on XTS compounds (including lead candidate XTS001), which are small-molecule inhibitors of VDAC1 oligomerization designed to restore mitochondrial function and prevent neuronal death across neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. The company also employs precision biomarkers for patient selection and monitoring. Founded in 2024 and based in Gainesville, FL, X-tosis's approach is built on over two decades of research by Professor Varda Shoshan-Barmatz.

Differentiator

Problem solved

Functional benefit

Brands

• MitoXTS: A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization, representing the company's core therapeutic platform technology.

Products and services

• MitoXTS™ Platform A patented family of small-molecule inhibitors of voltage-dependent anion channel 1 (VDAC1) oligomerization designed to restore mitochondrial function, reduce inflammation, and prevent neuronal death for neurodegenerative disease treatment. The platform is licensed to pharmaceutical partners across multiple indications.
• XTS001 Lead brain-penetrant, orally available small molecule drug candidate that selectively inhibits VDAC1 oligomerization for the treatment of Parkinson's disease and other neurodegenerative conditions. Demonstrated in preclinical models to reduce neuronal loss, restore dopamine levels, preserve mitochondrial function, and protect against PD-associated pathologies.
• XTS Compounds First-in-class mitochondrial therapeutics that target mitochondrial dysfunction by inhibiting VDAC1 oligomerization, applicable across multiple neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Available for licensing and partnership opportunities across multiple indications.
• Precision Biomarkers Biomarkers used for patient selection, treatment guidance, and monitoring as part of the company's precision medicine approach to neurodegenerative disease treatment.

Quantifiable outcome

• Robust efficacy in Alzheimer's and Parkinson's preclinical models including reductions in neuronal loss, improvements in cognitive function, restoration of mitochondrial activity, and mitigation of inflammation
• +6 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Denali Therapeutics: Public clinical-stage biotech with a broad neurodegenerative and lysosomal storage disease pipeline, including BBB-penetrant small molecules. Comparable as a well-capitalized developer of disease-modifying CNS therapeutics, though operating at much larger scale across multiple targets.
• Prothena Corporation: Clinical-stage biotech developing protein-targeted therapeutics for neurodegenerative diseases including Parkinson's and ALS. Comparable as a CNS-focused biotech pursuing disease-modifying approaches, though working in biologics rather than small molecules.

Direct peers

• Stealth BioTherapeutics: Clinical-stage company developing mitochondria-targeted therapeutics (elamipretide and pipeline candidates) for diseases involving mitochondrial dysfunction, including neurological and metabolic indications. Most directly comparable peer given shared focus on small-molecule mitochondrial modulators.
• Mission Therapeutics: UK-based clinical-stage biotech developing small-molecule mitophagy inducers and deubiquitinase inhibitors relevant to mitochondrial and neurological diseases. Comparable as a small-molecule developer addressing mitochondrial and CNS pathology.
• Khondrion BV: Clinical-stage pharmaceutical company developing small-molecule therapies that target mitochondrial dysfunction for inherited mitochondrial diseases and related neurological conditions. Closely aligned in modality (small molecules), target (mitochondria), and therapeutic area (neurology).
• Abliva AB: Swedish clinical-stage biotech developing mitochondrial medicine for primary mitochondrial disease and neurological indications. Directly comparable as a small-cap mitochondrial therapeutics developer pursuing CNS and rare disease applications.

Emerging players

• CervoMed (formerly Neuraly): Clinical-stage biotech developing CNS therapeutics for neurodegenerative diseases including dementia with Lewy bodies and Parkinson's. Comparable as a small-cap clinical-stage CNS drug developer pursuing neurodegenerative indications.
• Cortexyme: Clinical-stage biotech developing small-molecule therapeutics targeting bacterial virulence and neurodegeneration for Alzheimer's disease. Comparable as a small-molecule disease-modifying CNS developer.
• Annovis Bio: Clinical-stage biotech developing small-molecule therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable as a small-cap CNS-focused drug developer pursuing disease-modifying mechanisms.
• Pretzel Therapeutics: Private biotechnology company developing precision therapies for mitochondrial diseases using small molecules and biologics. Comparable as a venture-backed platform mitochondrial therapeutics company pursuing multiple indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/104229887

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X-tosis